Abstract
Introduction
Antihormonal cancer therapies are a class of drugs used predominantly in the
treatment of breast cancer and prostate cancer. The high incidence of these
tumor types translates into a significant commercial potential for drug
developers. Collectively, the antihormonal therapy cancer brands generated
sales of about $6.9 billion in the seven major pharmaceutical markets in 2008.
Key reasons to purchase this research
- Quantify the performance of each of the marketed antihormonal therapy
cancer brands in the seven major markets over the period 2008 to 2018
- Acquire a detailed account of antihormonal therapy cancer brand dynamics
and the events that drive and limit their market growth
- Benchmark the antihormonal therapy cancer brands against generics and rest
of class and align their 7MM performance with a rest of world snapshot
| 
View Cart
